Clinical Trials Browser

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT06263491 2026-03-11

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Phase 2 Recruiting

50 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Phase 2 Active not recruiting

33 enrolled 16 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05976763 2026-03-04

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Phase 3 Recruiting

421 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT03267433 2026-03-02

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Phase 3 Active not recruiting

689 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT04115631 2026-03-02

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

360 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT06522386 2026-03-02

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Phase 2 Recruiting

40 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT06854003 2026-02-20

BRAZAN

Phase 2 Recruiting

60 enrolled

Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

113 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT02446236 2026-02-19

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Phase 1 Active not recruiting

27 enrolled 11 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT02972840 2026-02-18

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase 3 Active not recruiting

635 enrolled 1 FDA

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2 Active not recruiting

51 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT06564038 2026-02-05

Soundtrack-E

Phase 1/2 Recruiting

276 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Phase 1/2 Completed

803 enrolled 2 FDA

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating